CRA (OPS): A Refrigerator Door Left Ajar Over the Weekend

Containment first, decisions second.

• Quarantine everything in that refrigerator, not just the kits that 'look' affected. Physically segregate the 22 kits, label them QUARANTINE - DO NOT DISPENSE, and keep them in a monitored location. Do not discard or return them: a stability assessment may permit use, and destruction would destroy the evidence.
• Initiate sponsor notification the same day via the clinical/QA contact, with the full logger download (not just a screenshot of the spike), kit numbers and lot numbers, exposure duration, and the dispensing dates for the three subjects.
• Stop dispensing from that unit until written sponsor authorisation is received. Verbal clearance is not sufficient.
• Retrieve the full logger history and check whether the 10 February review was signed off as 'in range' - if so, the log review process itself is broken, which is a separate finding.
• Do not unblind or stop subjects on your own initiative. The CRA's job is to present facts and obtain the medical monitor's assessment of product integrity.
• Record all of this in the monitoring report with times and names, and confirm the site has a functional backup refrigeration arrangement.

The CRA does not decide this alone, but must ensure the decision is made by the right people and documented.

• The sponsor's pharmaceutical sciences/medical monitor evaluates the excursion against available stability data (duration, peak, cumulative exposure) and issues a written disposition: product acceptable, product compromised, or conditional with enhanced monitoring.
• If product is judged compromised, subjects may have received subpotent or degraded drug. That is not automatically a safety emergency, but it is a protocol deviation and a potential efficacy confounder for those three subjects. They should be flagged in the clinical database for sensitivity analysis rather than silently pooled with compliant subjects.
• The investigator assesses each subject clinically and documents the discussion; if the sponsor directs a treatment change, that instruction is filed and implemented.
• Assess whether the event meets criteria for reporting to the IRB as a deviation or unanticipated problem.
• The site must not tell subjects 'the drug was probably fine' before the sponsor's written determination exists.

Accountability:

• Reconcile every kit in the unit: received, dispensed, returned, destroyed, quarantined. The numbers must balance; any unexplained kit is a separate finding.
• Record kit numbers dispensed to 3021, 3024, 3027 and cross-reference to the excursion window.
• File the logger download and the 10 February review sheet in the pharmacy/regulatory binder - these are source documents and essential records.

Documentation: deviation entry with root cause (unsupervised weekend access, door ajar), impact assessment, and the sponsor's written disposition attached.

Preventive actions:

• Door alarm or self-closing hinge; restricted after-hours access.
• Weekly (not occasional) log review by a named, trained reviewer with dated signature and a defined escalation step if out of range.
• Retraining of the pharmacy technician who missed the spike, with documented attendance.
• Written procedure stating that a flagged excursion triggers immediate quarantine and same-day sponsor contact.

Re-audit the corrective actions at the next visit rather than accepting them on paper.